Navigation Links
BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
Date:12/16/2013

r advanced clinical development and/or commercialization.

BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc. and is in the midst of a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions, which is expected to commence a pivotal CE-mark registration trial in early 2014; BL-8040 for treating acute myeloid leukemia (AML) and other hematological indications, which is in the midst of a Phase 2 study; and BL-7010 for celiac disease, which is expected to commence a Phase 1/2 study by the end of 2013.

For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.

Various statements in this release concerning BioLineRx's future expectations, including specifically those related to the development and commercialization of BL-8040, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of n
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
2. BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
3. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
4. BioLineRx Reports Third Quarter 2013 Financial Results
5. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
6. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
7. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
8. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
9. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
10. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
11. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Pharma IQ, after ... successful Serialisation Countdown calendar to cover the years 2014 ... pharmaserialisation.com shows the serialisation requirements around the globe ... into force. For companies dealing with international ... but "when" they will have to comply with new ...
(Date:9/18/2014)... 2014 MiMedx Group, Inc. (NASDAQ: ... marketer of patent protected regenerative biomaterials and bioimplants ... it has entered into a distribution agreement with ... its dehydrated human amnion/chorion membrane ("dHACM") allograft products ... a private label basis. The MiMedx ...
(Date:9/18/2014)... 2014  Zacks.com announces the list of stocks featured ... Research analysts discuss the latest news and events impacting ... the blog include the Avanir Pharmaceuticals (Nasdaq: AVNR - ... Free Report ), Orexigen (Nasdaq: OREX - Free ... ) and Gilead (Nasdaq: GILD - Free Report ...
Breaking Medicine Technology:Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6
(Date:9/18/2014)... It’s been just a few short weeks since ... splint to website visitors, but already the response has been ... delighted. It is perfect and I find it sooo much ... YOU FOR LISTENING!!!" Another user compared the original design ... to slip to the end of my toe. Now that ...
(Date:9/18/2014)... LAKE, Wis. (PRWEB) September 18, 2014 It ... and engage in health and wellness. Once again, Evensong ... in Spa Week by offering three services at a special ... Evensong Spa, managed by Marcus Hotels & Resorts , ... a national event encouraging Americans to embrace health and wellness ...
(Date:9/18/2014)... 2014 (HealthDay News) -- Daily supplements of selenium or ... development of age-related cataracts among men, a new study ... or both could help prevent cataracts. To investigate this ... Harvard Medical School in Boston, and his colleagues examined ... vitamin E. The trial was initially designed to study ...
(Date:9/18/2014)... In 2003, the government ... Barrio Adentro), which it hoped would increase ... Section 6.1.3.). In 2009, it invested VEF28 ... of Pharmaceutical Elaborations (Servicio Autónomo de Elaboraciones ... at a cheaper rate than private pharmaceutical ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Qualis Health, ... has published a white paper, “Advancing Primary Care ... Health Information Technology.” , Authors Jeff Hummel, MD, ... provide guidance to organizations engaged in the work of ... health IT can bolster PCMH objectives, such as generating ...
Breaking Medicine News(10 mins):Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3Health News:Evensong Spa Celebrates Spa Week with $50 Services 2Health News:Evensong Spa Celebrates Spa Week with $50 Services 3Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2
... Reduce Stiffness for Better Health with,Innovative ,Sleep and ... FORT LAUDERDALE, Fla., Jan. 9 Contour ... people implement an,ergonomic makeover into their life for ... well being. By aligning the body, relieving,pressure points ...
... Makes Available New Daily Dosing Option for the Treatment ... and Company,(NYSE: LLY ) announced today that the ... for once daily use (2.5 mg and,5 mg), an ... dysfunction,(ED). When Cialis for once daily use is taken ...
... private equity, public offering, ... Irell represents leading clients in gaming, green tech, ... construction, LOS ANGELES, Jan. 8 Irell & Manella ... corporate deals,valued at more than $7 billion., The firm ...
... years, The Leukemia &,Lymphoma Society has organized "Team ... achieve personal goals and most of all, raised,over ... video from The Leukemia & Lymphoma Society at:, ... In Training" helps,individuals prepare for a full marathon ...
... Red Cross,announced today that J. Chris Hrouda has ... for the organization,s Biomedical Services., Hrouda will ... Each year the American Red Cross collects approximately ... million blood products to,patients at approximately 3,000 hospitals ...
... 8 Conseco, Inc. (NYSE:,CNO) announced that Todd M. ... senior vice president and treasurer. He will report to ... Hacker joins Conseco from YRC Worldwide, where he was ... treasurer from,2004-2005. From 2005-2006, he was senior vice president, ...
Cached Medicine News:Health News:Renew, Relax & Align the Body with an Ergonomic Makeover 2Health News:Renew, Relax & Align the Body with an Ergonomic Makeover 3Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 2Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 3Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 4Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 5Health News:Irell & Manella Posts Strong Year for Corporate Transactions 2Health News:Irell & Manella Posts Strong Year for Corporate Transactions 3Health News:Irell & Manella Posts Strong Year for Corporate Transactions 4Health News:Irell & Manella Posts Strong Year for Corporate Transactions 5Health News:Irell & Manella Posts Strong Year for Corporate Transactions 6Health News:American Red Cross Announces New Leader for Biomedical Services 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: